Hot melt extrusion, a continuous manufacturing process, has emerged as a leading technology for solid dispersions of poorly soluble drugs. For many APIs, hot melt extrusion has improved solubility and bioavailability, allowing for lower doses and reduced production costs. Hot melt extrusion is also ideally suited for drug/polymer formulations used in combination devices, bio-resorbable implants and temporary implants.
Development and feasibility of drug/polymer formulations
Full characterization and testing of drug/polymer formulations
Clean Room melt extrusion for pharmaceuticals and implantable drug/device combination products
A significant number of new active pharmaceutical ingredients (APIs) are poorly water soluble and cannot be formulated and processed with traditional aqueous methods. Hot melt extrusion (HME) has become an effective solubilization tool in improving the dissolution rate of poorly water soluble drugs to enhance their bioavailability after oral administration1. These crystalline hydrophobic drugs can be dispersed in hydrophilic polymers using HME to manufacture amorphous solid dispersions.
Visit our team at the 3rd Advancing Drug Development Forum on December 6th, 2018 at the Liberty Hotel in Boston, Massachusetts.
Visit Foster Delivery Science at the 5th Annual Controlled & Modified Drug Release Summit on November 28-29, 2018 at the Marriott Philadelphia Downtown Hotel in Philadephia, PA.
Join us in Booth 1808 during the AAPS Pharm Sci 360 Annual Meeting & Exposition on November 4-7th at the Walter E. Washington Convention Center.
Cras justo odio, dapibus ac facilisis in, egestas eget quam. Donec id elit
